Invesco Ltd. Acquires 21,266 Shares of Addus HomeCare Co. (NASDAQ:ADUS)

Invesco Ltd. grew its holdings in Addus HomeCare Co. (NASDAQ:ADUS) by 6.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 346,120 shares of the company’s stock after purchasing an additional 21,266 shares during the quarter. Invesco Ltd.’s holdings in Addus HomeCare were worth $43,386,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC grew its stake in Addus HomeCare by 324.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 280 shares of the company’s stock valued at $35,000 after purchasing an additional 214 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Addus HomeCare by 38.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 531 shares of the company’s stock valued at $67,000 after buying an additional 148 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Addus HomeCare in the 4th quarter worth approximately $77,000. Harvest Fund Management Co. Ltd bought a new position in shares of Addus HomeCare during the 4th quarter worth approximately $86,000. Finally, KBC Group NV raised its stake in shares of Addus HomeCare by 49.1% during the 4th quarter. KBC Group NV now owns 814 shares of the company’s stock worth $102,000 after acquiring an additional 268 shares in the last quarter. Hedge funds and other institutional investors own 95.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ADUS. Macquarie restated an “outperform” rating and issued a $129.00 target price on shares of Addus HomeCare in a research note on Thursday, February 27th. StockNews.com downgraded Addus HomeCare from a “buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Oppenheimer increased their price target on Addus HomeCare from $145.00 to $150.00 and gave the company an “outperform” rating in a research note on Friday, January 24th. Stephens restated an “overweight” rating and set a $142.00 price target on shares of Addus HomeCare in a research note on Wednesday, March 12th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $150.00 price objective on shares of Addus HomeCare in a research report on Thursday, April 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Addus HomeCare presently has a consensus rating of “Moderate Buy” and an average price target of $132.78.

Addus HomeCare Stock Up 1.8 %

Addus HomeCare stock opened at $101.00 on Thursday. The stock has a 50-day moving average price of $100.02 and a 200 day moving average price of $117.53. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 23.11, a price-to-earnings-growth ratio of 1.41 and a beta of 0.93. Addus HomeCare Co. has a 52 week low of $87.88 and a 52 week high of $136.72.

Addus HomeCare (NASDAQ:ADUS) last released its quarterly earnings data on Monday, February 24th. The company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.35 by ($0.09). Addus HomeCare had a net margin of 6.50% and a return on equity of 9.62%. The business had revenue of $297.14 million during the quarter, compared to analysts’ expectations of $291.04 million. Research analysts anticipate that Addus HomeCare Co. will post 4.59 EPS for the current fiscal year.

Addus HomeCare Company Profile

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.